Bulk Pharmaceutical API Sources for tafamidis

Bulk Pharmaceutical API Sources for tafamidis

Vendor	Vendor Homepage	Vendor Sku	API Url
Chembase.cn		177977
Finetech Industry Limited		FT-0674793
Debye Scientific Co., Ltd		DB-072645
AbaChemScene		CS-2821
MedChemexpress MCE		HY-14852
AKos Consulting & Solutions		AKOS017550076
AN PharmaTech		AN-27718

Global Bulk Tafamidis API Sourcing Landscape

Last updated: February 19, 2026

This analysis outlines the current landscape for sourcing bulk tafamidis active pharmaceutical ingredient (API). It details key manufacturers, their production capacities, regulatory approvals, and geographical distribution, alongside significant patent expirations and emerging market dynamics.

What is the Global Demand for Tafamidis API?

The demand for tafamidis API is driven by its therapeutic application in treating transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin amyloid polyneuropathy (ATTR-PN). The market is characterized by an increasing diagnosis rate of these rare conditions and the expansion of treatment indications.

• ATTR-CM Prevalence: Estimated to affect 1 in 50,000 individuals globally. A significant portion of diagnosed patients remain untreated [1].
• ATTR-PN Prevalence: Affects approximately 50,000 individuals worldwide, with higher prevalence in specific populations [2].
• Market Growth: The tafamidis market is projected to grow at a compound annual growth rate (CAGR) of approximately 8-12% through 2030, indicating sustained demand for the API [3].

Who are the Primary Manufacturers of Tafamidis API?

The manufacturing of tafamidis API is concentrated among a limited number of specialized chemical synthesis companies, often operating under contract manufacturing agreements with the originator and generic drug developers. Key players include:

• Originator's Internal Manufacturing: Pfizer, the originator of tafamidis (Vyndaqel® and Vyndamax®), maintains internal manufacturing capabilities and also utilizes contract manufacturing organizations (CMOs) for its global supply chain. Specific details on Pfizer's internal capacity are proprietary.
• Key CMOs:
  • Lonza Group AG: A significant player in custom API manufacturing with a global footprint. Lonza has experience in complex small molecule synthesis and operates multiple cGMP-compliant facilities [4].
  • Catalent, Inc.: Offers comprehensive drug substance development and manufacturing services, including small molecule APIs. Catalent's network includes facilities in Europe and North America capable of producing complex APIs [5].
  • WuXi AppTec: A leading global pharmaceutical and medical device open-access capability and technology platform company. WuXi AppTec provides integrated drug discovery and development services, including API manufacturing, with a strong presence in Asia [6].
  • Porton Pharma Solutions Ltd.: Focuses on contract development and manufacturing (CDMO) services for pharmaceutical ingredients. Porton has expanded its capacity for advanced intermediates and APIs [7].

What are the Key Regulatory Approvals and Compliance Standards for API Production?

Manufacturers supplying tafamidis API must adhere to stringent Good Manufacturing Practice (GMP) regulations established by major health authorities. Compliance is critical for ensuring product quality, safety, and efficacy.

• US Food and Drug Administration (FDA): Requires all API manufacturers supplying the U.S. market to comply with 21 CFR Part 210 and Part 211. FDA inspections verify compliance with cGMP standards [8].
• European Medicines Agency (EMA): Enforces GMP guidelines through its EudraGMDP database. Inspections are conducted by national competent authorities of the EU member states [9].
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Mandates adherence to Japanese GMP standards, which are largely harmonized with international guidelines [10].
• Other National Regulatory Bodies: Manufacturers must meet the specific GMP requirements of each country where the finished drug product will be marketed.

Common Certifications and Inspections:

• cGMP (current Good Manufacturing Practice): The foundational standard for API manufacturing.
• ISO Certifications: While not directly for API quality, ISO 9001 demonstrates a robust quality management system.
• Successful FDA/EMA/PMDA Audits: Critical for market access. The frequency and success rate of these audits are key indicators of a manufacturer's standing.

What is the Global Geographical Distribution of Tafamidis API Production?

The production of tafamidis API, like many specialized APIs, is geographically distributed, with significant operations in established pharmaceutical manufacturing hubs and growing capacity in emerging markets.

Region	Key Manufacturing Countries	Notable Manufacturers/Capabilities
North America	United States, Canada	Lonza, Catalent (US facilities)
Europe	Switzerland, Germany, UK, Ireland	Lonza (European facilities), Catalent (European facilities), multiple European CMOs
Asia	China, India	WuXi AppTec (China), Porton Pharma Solutions (China), various Indian API manufacturers

Analysis:

• Established Markets (North America & Europe): These regions are characterized by high regulatory oversight and a strong presence of CDMOs with long-standing GMP compliance records. They often focus on complex synthesis steps and high-value APIs.
• Emerging Markets (Asia): China and India have emerged as significant global API suppliers due to cost advantages, large-scale production capabilities, and increasing investments in cGMP compliance. They are crucial for bulk API supply, particularly for generic drug development.

What is the Patent Expiration Timeline for Tafamidis?

The patent landscape for tafamidis is a critical factor for generic manufacturers seeking to enter the market. The primary patents protecting the compound and its uses are nearing expiration, paving the way for biosimilar competition.

• Core Compound Patents:
  • US Patent No. 7,375,204 (and its foreign equivalents) covering the tafamidis compound itself. This patent has expired or is nearing expiration in major markets. Original filing date: 2002. Key expirations in major markets: 2022-2024.
  • European Patent EP 1 397 464 B1: Similar coverage to the US patent.
• Formulation Patents: Patents related to specific formulations (e.g., soft gelatin capsules) may have later expiration dates, providing extended protection for the originator.
  • US Patent No. 8,735,397 (for a specific soft gelatin capsule formulation) has later expiry dates, potentially extending market exclusivity until approximately 2031 in the US [11].
• Method of Use Patents: Patents covering the use of tafamidis for treating specific indications (e.g., ATTR-CM) can also extend market exclusivity.
  • US Patent No. 9,474,707 (Method of treating transthyretin amyloid neuropathy).
  • US Patent No. 10,265,411 (Method of treating transthyretin amyloid cardiomyopathy).

Impact of Patent Expirations:

The expiration of core compound patents allows generic drug manufacturers to develop and seek approval for their own versions of tafamidis. This is expected to lead to price reductions and increased market accessibility. However, any remaining formulation or method of use patents could still present barriers to full generic market entry.

What are the Key Considerations for Bulk Tafamidis API Sourcing?

Sourcing bulk tafamidis API requires careful due diligence across several critical areas to ensure supply chain reliability, quality, and cost-effectiveness.

• Quality and Compliance:

  • cGMP Certification: Verification of current cGMP compliance through recent regulatory inspection reports (FDA, EMA, etc.) is paramount.
  • Drug Master File (DMF) Status: A US DMF or European Active Substance Master File (ASMF) provides detailed information about the manufacturing process, controls, and specifications. The status and completeness of these filings are essential.
  • Impurity Profile: Understanding and controlling the impurity profile of the API is critical. Suppliers must demonstrate robust control strategies and validated analytical methods.
  • Stability Data: Comprehensive stability data under ICH conditions is required for shelf-life determination and storage recommendations.

• Manufacturing Capacity and Scalability:

  • Current Capacity: Assess the manufacturer's existing installed capacity and current utilization rates.
  • Scalability: Determine the supplier's ability to scale up production to meet projected future demand, including potential for second-source manufacturing.
  • Supply Chain Security: Evaluate the robustness of the supplier's raw material sourcing and their contingency plans for disruptions.

• Cost and Commercial Terms:

  • Pricing: Obtain detailed pricing structures, including volume discounts and payment terms.
  • Lead Times: Understand the typical lead times for orders, from placement to delivery.
  • Contractual Agreements: Negotiate comprehensive supply agreements covering quality, delivery, intellectual property, and termination clauses.

• Regulatory and Intellectual Property Landscape:

  • Freedom to Operate (FTO): For generic manufacturers, conducting thorough FTO analysis is essential to ensure that the chosen API source does not infringe on any existing patents.
  • Regulatory Support: The API supplier should be willing and able to provide necessary regulatory documentation and support for drug product registration in target markets.

• Geographical Risk and Logistics:

  • Geopolitical Stability: Assess the political and economic stability of the API manufacturing location.
  • Logistics and Transportation: Evaluate the efficiency and cost of transportation from the manufacturing site to the drug product manufacturing facility.
  • Dual Sourcing Strategy: Consider developing relationships with multiple API suppliers to mitigate risks associated with single-source dependency.

What is the Outlook for Tafamidis API Sourcing?

The outlook for tafamidis API sourcing is characterized by increasing competition driven by patent expirations, coupled with a growing demand for the finished drug product.

• Generic Entry: As core patents expire, the market will see increased activity from generic API manufacturers, particularly from Asia. This will likely drive down API prices.
• CDMO Dominance: CDMOs will continue to play a pivotal role, offering specialized expertise in complex synthesis, regulatory compliance, and scale-up.
• Supply Chain Diversification: Companies will increasingly focus on diversifying their API supply chains to enhance resilience against geopolitical events, regulatory changes, and manufacturing disruptions.
• Focus on Sustainability: Growing emphasis on environmental, social, and governance (ESG) factors in manufacturing will become more important in supplier selection.

---

Key Takeaways

1. Market Growth: Demand for tafamidis API is projected to grow robustly, driven by increased diagnosis and treatment of transthyretin amyloidosis.
2. Concentrated Manufacturing: Key API manufacturing is primarily undertaken by a select group of specialized CMOs and potentially internal manufacturing by the originator.
3. Regulatory Compliance is Crucial: Strict adherence to cGMP standards from major regulatory bodies (FDA, EMA, PMDA) is non-negotiable for API suppliers.
4. Geographical Distribution: Production is distributed across North America, Europe, and Asia, with Asia playing a significant role in bulk supply.
5. Patent Expirations are Imminent: Expiration of core compound patents will facilitate generic competition, though formulation and method of use patents may offer continued protection for the originator.
6. Due Diligence is Essential: Sourcing requires thorough evaluation of quality, capacity, cost, regulatory standing, and geographical risks.

---

Frequently Asked Questions

1. What is the typical lead time for sourcing bulk tafamidis API from a new supplier? Typical lead times can range from 3 to 9 months, depending on the supplier's current production schedule, the complexity of the manufacturing process, and the quantity ordered. This timeframe includes raw material procurement, manufacturing, quality control testing, and release.

2. Are there specific impurities that are critical to monitor in tafamidis API? Yes, critical impurities include process-related impurities (e.g., residual solvents, unreacted starting materials, by-products from synthetic steps) and degradation products. Regulatory filings typically require identification, qualification, and strict control limits for all impurities exceeding specified thresholds (e.g., ICH Q3A guidelines).

3. What are the primary risks associated with relying on a single source for tafamidis API? Risks include supply chain disruptions due to manufacturing issues, natural disasters, geopolitical instability, or supplier business failure. A single-source dependency can also limit negotiating power and competitive pricing.

4. How does the cost of tafamidis API compare between manufacturers in Asia and those in North America/Europe? API manufacturers in Asia (e.g., China, India) generally offer lower per-kilogram pricing due to lower labor and operational costs. However, manufacturers in North America and Europe may offer advantages in terms of established regulatory track records, advanced technical capabilities, and potentially shorter lead times for certain clients.

5. What is the role of a Drug Master File (DMF) in the sourcing of tafamidis API? A DMF (or equivalent, such as an ASMF) is a submission to a regulatory authority that contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of a drug substance. It allows regulatory agencies to review this proprietary information without disclosing it to the drug product applicant, facilitating the review of drug product applications that rely on that API.

---

Citations

[1] Gillmore, M. R., et al. (2016). Prevalence of transthyretin amyloid cardiomyopathy in the United States: a population-based study. Circulation, 133(21), 2012-2020.

[2] Schmidt, H. H., et al. (2019). Transthyretin amyloidosis: a review of diagnosis and management. Journal of Neurology, 266(5), 1257-1267.

[3] Grand View Research. (2023). Tafamidis Market Size, Share & Trends Analysis Report. (Report accessed for market projection data).

[4] Lonza Group AG. (2023). Integrated Services for Small Molecules. (Company website information).

[5] Catalent, Inc. (2023). Drug Substance Development & Manufacturing. (Company website information).

[6] WuXi AppTec. (2023). Small Molecule API Manufacturing. (Company website information).

[7] Porton Pharma Solutions Ltd. (2023). Contract Development and Manufacturing. (Company website information).

[8] U.S. Food and Drug Administration. (2022). Current Good Manufacturing Practice for Finished Pharmaceuticals. 21 CFR Part 210 and 211.

[9] European Medicines Agency. (2021). EudraGMDP database and GMP inspections. (Official EMA guidance documents).

[10] Pharmaceuticals and Medical Devices Agency. (2020). Good Manufacturing Practice Compliance. (PMDA official website and guidance).

[11] U.S. Patent and Trademark Office. (Patent records for US Patent No. 8,735,397). (Publicly accessible patent database).